Cytosorbents (CTSO) Competitors

Cytosorbents (NASDAQ:CTSO) and AVITA Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Which has stronger valuation and earnings, CTSO or RCEL?

Cytosorbents has higher earnings, but lower revenue than AVITA Medical. AVITA Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$35.59M	1.71	-$28.51M	-$0.38	-2.56
AVITA Medical	$64.25M	3.52	-$61.85M	-$2.39	-3.61

Do insiders & institutionals have more ownership in CTSO or RCEL?

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 27.7% of AVITA Medical shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Comparatively, 1.8% of AVITA Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts rate CTSO or RCEL?

Cytosorbents presently has a consensus target price of $4.67, suggesting a potential upside of 380.11%. AVITA Medical has a consensus target price of $17.25, suggesting a potential upside of 100.12%. Given Cytosorbents' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cytosorbents is more favorable than AVITA Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
AVITA Medical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is CTSO or RCEL more profitable?

Cytosorbents has a net margin of -49.47% compared to AVITA Medical's net margin of -96.26%. Cytosorbents' return on equity of -118.54% beat AVITA Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-49.47%	-118.54%	-42.31%
AVITA Medical	-96.26%	-337.91%	-71.50%

Does the media refer more to CTSO or RCEL?

In the previous week, Cytosorbents had 11 more articles in the media than AVITA Medical. MarketBeat recorded 17 mentions for Cytosorbents and 6 mentions for AVITA Medical. Cytosorbents' average media sentiment score of 0.97 beat AVITA Medical's score of 0.31 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AVITA Medical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer CTSO or RCEL?

Cytosorbents received 358 more outperform votes than AVITA Medical when rated by MarketBeat users. Likewise, 73.50% of users gave Cytosorbents an outperform vote while only 70.34% of users gave AVITA Medical an outperform vote.

Company	Underperform	Outperform
Cytosorbents	Outperform Votes 441 73.50%	Underperform Votes 159 26.50%
AVITA Medical	Outperform Votes 83 70.34%	Underperform Votes 35 29.66%

Which has more volatility and risk, CTSO or RCEL?

Cytosorbents has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, AVITA Medical has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Summary

Cytosorbents beats AVITA Medical on 15 of the 19 factors compared between the two stocks.